Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Independent real-world application of a clinical-grade automated prostate cancer detection system.
da Silva LM, Pereira EM, Salles PG, Godrich R, Ceballos R, Kunz JD, Casson A, Viret J, Chandarlapaty S, Ferreira CG, Ferrari B, Rothrock B, Raciti P, Reuter V, Dogdas B, DeMuth G, Sue J, Kanan C, Grady L, Fuchs TJ, Reis-Filho JS. da Silva LM, et al. Among authors: chandarlapaty s. J Pathol. 2021 Jun;254(2):147-158. doi: 10.1002/path.5662. Epub 2021 Apr 27. J Pathol. 2021. PMID: 33904171 Free PMC article.
Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
Peters S, Loi S, André F, Chandarlapaty S, Felip E, Finn SP, Jänne PA, Kerr KM, Munzone E, Passaro A, Pérol M, Smit EF, Swanton C, Viale G, Stahel RA. Peters S, et al. Among authors: chandarlapaty s. Ann Oncol. 2024 Jul;35(7):607-629. doi: 10.1016/j.annonc.2024.04.002. Epub 2024 Apr 20. Ann Oncol. 2024. PMID: 38648979 Review.
eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer.
Boyer JA, Sharma M, Dorso MA, Mai N, Amor C, Reiter JM, Kannan R, Gadal S, Xu J, Miele M, Li Z, Chen X, Chang Q, Pareja F, Worland S, Warner D, Sperry S, Chiang GG, Thompson PA, Yang G, Ouerfelli O, de Stanchina E, Wendel HG, Rosen EY, Chandarlapaty S, Rosen N. Boyer JA, et al. Among authors: chandarlapaty s. bioRxiv [Preprint]. 2024 May 11:2024.05.08.593195. doi: 10.1101/2024.05.08.593195. bioRxiv. 2024. PMID: 38766126 Free PMC article. Preprint.
Predictors of Response to CDK4/6i Retrial After Prior CDK4/6i Failure in ER+ Metastatic Breast Cancer.
Mai N, Dos Anjos CH, Razavi P, Safonov A, Patil S, Chen Y, Drago JZ, Modi S, Bromberg JF, Dang CT, Liu D, Norton L, Robson M, Chandarlapaty S, Jhaveri K. Mai N, et al. Among authors: chandarlapaty s. Res Sq [Preprint]. 2024 May 2:rs.3.rs-4237867. doi: 10.21203/rs.3.rs-4237867/v1. Res Sq. 2024. Update in: NPJ Breast Cancer. 2024 Oct 18;10(1):92. doi: 10.1038/s41523-024-00699-3 PMID: 38746324 Free PMC article. Updated. Preprint.
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.
Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr RA, Weigelt B, Hanker AB, Chandarlapaty S, King TA, Reis-Filho JS, Arteaga CL, Park SY, Michor F, Polyak K. Janiszewska M, et al. Among authors: chandarlapaty s. Nat Genet. 2015 Oct;47(10):1212-9. doi: 10.1038/ng.3391. Epub 2015 Aug 24. Nat Genet. 2015. PMID: 26301495 Free PMC article.
ESR1 and endocrine therapy resistance: more than just mutations.
Piscuoglio S, Ng CKY, Weigelt B, Chandarlapaty S, Reis-Filho JS. Piscuoglio S, et al. Among authors: chandarlapaty s. Ann Oncol. 2018 Apr 1;29(4):787-789. doi: 10.1093/annonc/mdy081. Ann Oncol. 2018. PMID: 29522117 Free PMC article. No abstract available.
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.
Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, Hsieh W, Sanchez-Vega F, Brown DN, Da Cruz Paula AF, Morris L, Selenica P, Eichenberger E, Shen R, Schultz N, Rosen N, Scaltriti M, Brogi E, Baselga J, Reis-Filho JS, Chandarlapaty S. Li Z, et al. Among authors: chandarlapaty s. Cancer Cell. 2018 Dec 10;34(6):893-905.e8. doi: 10.1016/j.ccell.2018.11.006. Cancer Cell. 2018. PMID: 30537512 Free PMC article.
Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care.
Penson A, Camacho N, Zheng Y, Varghese AM, Al-Ahmadie H, Razavi P, Chandarlapaty S, Vallejo CE, Vakiani E, Gilewski T, Rosenberg JE, Shady M, Tsui DWY, Reales DN, Abeshouse A, Syed A, Zehir A, Schultz N, Ladanyi M, Solit DB, Klimstra DS, Hyman DM, Taylor BS, Berger MF. Penson A, et al. Among authors: chandarlapaty s. JAMA Oncol. 2020 Jan 1;6(1):84-91. doi: 10.1001/jamaoncol.2019.3985. JAMA Oncol. 2020. PMID: 31725847 Free PMC article.
Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas.
Pareja F, Toss MS, Geyer FC, da Silva EM, Vahdatinia M, Sebastiao APM, Selenica P, Szatrowski A, Edelweiss M, Wen HY, Mihai R, Varga Z, Foschini MP, Rubin BP, Ellis IO, Chandarlapaty S, Jungbluth AA, Brogi E, Weigelt B, Reis-Filho JS, Rakha EA. Pareja F, et al. Among authors: chandarlapaty s. Histopathology. 2020 May;76(6):865-874. doi: 10.1111/his.14057. Histopathology. 2020. PMID: 31887226 Free PMC article.
155 results